BioSpace News Archive

Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will present at two upcoming investor conferences in November 2020.

Company will invest $8.7 million in Mercy Drive neighborhood and expand its Project Health program as part of its nearly $600 million commitment to address racial inequality

Netcapital Inc. (OTC: VSTRD) announced that portfolio company Vymedic’s clinically proven antiviral will be delivered to market this December, in time for flu season

DILIsym Services, Inc., a Simulations Plus company and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, announced that the DILIsym liver safety software platform played a key role in public comments submitted to the State of California Office of Environmental Health Hazard Assessment.

Designed for At-Home, Business, and Institutional Use - Kits Aim to Eliminate Strain on Testing Facilities with High Frequency Testing

Ozone is a natural gas composed of three atoms of oxygen and is Scientifically Proven to Kill SARS Coronavirus and Influenza; Interest is Sparked in its Ability to Combat COVID-19

New pilot aims to help employers take a data-driven approach to addressing growing mental health crisis and its impact on employees across the country

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer.

Findings from a randomized controlled trial recently published in the Journal of the American College of Cardiology, indicate that people in their 60s and 70s who regularly consume walnuts may have reduced inflammation, a factor associated with a lower risk of heart disease, compared to those who do not eat walnuts.